Back to Search Start Over

Non-natural amino acids into LfcinB-derived peptides: effect in their (i) proteolytic degradation and (ii) cytotoxic activity against cancer cells.

Authors :
Insuasty-Cepeda DS
Barragán-Cárdenas AC
Ardila-Chantre N
Cárdenas-Martínez KJ
Rincón-Quiñones I
Vargas-Casanova Y
Ochoa-Zarzosa A
Lopez-Meza JE
Parra-Giraldo CM
Ospina-Giraldo LF
Fierro-Medina R
García-Castañeda JE
Rivera-Monroy ZJ
Source :
Royal Society open science [R Soc Open Sci] 2023 Jun 14; Vol. 10 (6), pp. 221493. Date of Electronic Publication: 2023 Jun 14 (Print Publication: 2023).
Publication Year :
2023

Abstract

The dimeric peptide <superscript>26</superscript> [F]: (RRWQWR F KKLG) <subscript>2</subscript> -K-Ahx has exhibited a potent cytotoxic effect against breast cancer cell lines, with position 26 (F) being the most relevant for anti-cancer activity. In this investigation, six analogues of the <superscript>26</superscript> [F] peptide were synthesized in which the 26th position was replaced by non-natural hydrophobic amino acids, finding that some modifications increased the resistance to proteolytic degradation exerted by trypsin or pepsin. Additionally, these modifications increased the cytotoxic effect against breast cancer cells and generated cell death mediated by apoptosis pathways, activating caspases 8 and 9, and did not compromise the integrity of the cytoplasmic membrane. Finally, it was found that the modified peptides have a broad spectrum of action, since they also have a cytotoxic effect against the HeLa human cervical cancer cell line. Peptide <superscript>26</superscript> [F] was inoculated in mice by ip administration and the lethal dose 50 (LD <subscript>50</subscript> ) was between 70 and 140 mg kg <superscript>-1</superscript> . While for the <superscript>26</superscript> [1-Nal]: (RRWQWR-1-Nal-KKLG) <subscript>2</subscript> -K-Ahx peptide, a dose-response test was performed, and the survival rate was 100%. These results suggested that these peptides are safe in this animal model and could be considered as promissory to develop a treatment against breast cancer.<br />Competing Interests: We declare we have no competing interests.<br /> (© 2023 The Authors.)

Details

Language :
English
ISSN :
2054-5703
Volume :
10
Issue :
6
Database :
MEDLINE
Journal :
Royal Society open science
Publication Type :
Academic Journal
Accession number :
37325596
Full Text :
https://doi.org/10.1098/rsos.221493